|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Sales, net | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Selling and administrative expenses | |||||
| Operating (loss) income | |||||
| Other income, net: | |||||
| Interest expense | |||||
| Unrealized gain (loss) on investment in iBio Stock | |||||
| Realized loss on sale of investment in iBio Stock | |||||
| Interest income, net | |||||
| Other income (expense), net | |||||
| Total other income, net | |||||
| (Loss) income before income taxes | |||||
| Income tax expense, net | |||||
| Net (loss) income | |||||
| Basic net (loss) income per common share (in dollars per share) | |||||
| Diluted net (loss) income per common share (in dollars per share) | |||||
| Weighted average common shares outstanding - basic (in shares) | |||||
| Add: Equivalent shares outstanding - stock options (in shares) | |||||
| Weighted average common shares outstanding - diluted (in shares) | |||||
Loading...
